Most Recent
The lead applicant in an $84 million class action against labour hire company WorkPac has been given the green light to intervene in an appeal that will clarify the definition of casual work for Australian employers.
Pharmaceutical giant Mylan has been ordered to hand over documents relating to its proposed launch of a generic version of its cholesterol drug Lipidil to rival Sun Pharma in advance of a hearing on Mylan's request for an order blocking Sun from launching its own generic version of the drug.
Labour hire company WorkPac has asked the court to dismiss an $84 million class action brought on behalf of thousands of casual mine workers alleging they were misclassified and denied annual leave and other entitlements.
The Australian Competition and Consumer Commission will not oppose the merger of two companies that own some of Australia's largest intellectual property boutiques.
An eight-day joint hearing in cases brought by Allergan alleging infringement of its Botox trade mark, which was due to commence Monday, has been unexpectedly vacated by the court, with barristers and legal teams left in the dark about the reasons.
An appeals court has dismissed a challenge by Veritas Advisory principal liquidator David Iannuzzi to the admissibility of evidence submitted by the Australian Taxation Office in the agency's case seeking compensation and a 10-year ban.
Baby food maker Bellamy's is not giving up its fight to limit the costs of two shareholder class actions against the company, lodging an appeal of a ruling that shut down its cost-capping bid as premature.
The Construction, Forestry, Maritime, Mining and Energy union is seeking court approval to intervene in a class action against labour hire company WorkPac on behalf of casual miners who claim they were denied annual leave and other entitlements.
The ABC paid ousted managing managing director Michelle Guthrie $730,000 to settle a lawsuit alleging unfair dismissal.
Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.